Goldman Sachs analyst Matthew Sykes downgraded Pacific Biosciences of California (NASDAQ: PACB) from Buy to Neutral with a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE